Faculty of Biology, Medicine and Health

The University of Manchester

  (MCRC Clinical) The VIGILANCE study: developing imaging and circulating biomarkers towards personalised radiotherapy in locally advanced lung cancer

  , , Dr Florent Mouliere  Friday, November 15, 2024  Competition Funded PhD Project (Students Worldwide)

About the Project

Lung cancer is the leading cause of cancer mortality worldwide. Non-small-cell lung cancer (NSCLC) is the most common type. One-fifth of patients present with stage 3 or locally advanced (LA) disease, equating to approximately 9,000 patients annually in England. Over half of these patients receive radiotherapy-based treatments. In fit patients, concurrent chemoradiotherapy followed by immunotherapy offers the best chance of cure. Unfortunately, such treatments are associated with significant toxicity and the prognosis remains poor due to high risk of recurrence.  

There remains an unmet clinical need for biomarkers that can predict toxicity and identify treatment failure early. Such information would be clinically useful for tailoring personalised treatment and follow-up regimens to individuals and their specific cancer. The ultimate aim is to design a patient-led clinical trial that integrates new biomarkers to improve treatment decision-making and individualises lung cancer treatment. 

High-quality prospective clinical data has already been collected from patients with LA-NSCLC undergoing curative-intent radiotherapy within the MCRC’s VIGILANCE study. Study data includes innovative cell-free DNA (cfDNA) biomarkers together with radiomic biomarkers from routine imaging captured at multiple timepoints throughout treatment and follow-up. Patient-reported symptoms and quality of life measures through patient-reported outcome measures have also been collected. This will provide insight into the patient experience during and after radiotherapy and permit the evaluation of the potential of these measures as a patient-centred qualitative biomarker. Except for cfDNA, all candidate biomarkers are routinely collected, making this study highly pragmatic.  

Overall, this project builds on previous work, but will introduce new and impactful insights that significantly advance the research. The candidate will benefit from the unique infrastructure and strengths that have been established locally, bringing together experts in clinical and translational research. The team includes members of the Christie, CRUK Lung Cancer Centre of Excellence, National Cancer Biomarker Centre and the MCRC.  

Eligibility 

You must be a post-registration clinician, and ideally have a specialist post in a related subject, to apply for our Clinical Research Training Fellowships. 

You should also hold, or about to obtain, a minimum Upper Second Class UK honours degree, or the equivalent qualifications gained outside the UK, in a relevant discipline. A related master’s degree would be an advantage.  

It is generally expected that CRTFs will return to a training programme in the UK upon completion of their research degree. 

International applicants (including EU nationals) must ensure they meet the academic eligibility criteria (including English language) before contacting potential supervisors to express an interest in their project. Eligibility information can be found on the University's Country Specific information page. 

Before you Apply 

Applicants must make direct contact with preferred supervisors before applying. It is your responsibility to make arrangements to meet with potential supervisors, prior to submitting a formal online application.  

How to Apply 

For information on how to apply for this project, please visit the Faculty of Biology, Medicine and Health Doctoral Academy website. On the online application form select MCRC PhD Programme. 

Your application form must be accompanied by a number of supporting documents by the advertised deadlines. Without all the required documents submitted at the time of application, your application will not be processed and we cannot accept responsibility for late or missed deadlines. Incomplete applications will not be considered.  If you have any queries regarding making an application, please contact our admissions team.  

Equality, Diversity and Inclusion  

Equality, diversity and inclusion is fundamental to the success of The University of Manchester, and is at the heart of all of our activities. The full Equality, diversity and inclusion statement can be found on the website. 

Applications Timeline 

Applications open: 11 October 2024 

Application deadline: 15 November 2024 

Interviews: 17th January 2025 

Start date: September 2025

Mathematics (25)

Funding Notes

The clinical fellowships are usually tenable over three years, although in certain circumstances they may be four years duration. The fellowship covers: running expenses, an appropriate salary in line with the applicant's current salary and grade and full coverage of University PhD fees at the UK/home fee rate. 

International Candidates 

We are able to offer a limited number of bursaries to high- performing EU and international candidates, covering PhD fees only. Bursaries do not include financial support for visa/health surcharges. We asses each EU and international candidate's suitability for a bursary at the application and interview stages. 


References

1. Horne A, Crawford H, Dempsey C, Faivre-Finn C. 162TiP An update on the VIGILANCE study: Developing circulating and imaging biomarkers towards personalised radiotherapy in lung cancer. ESMO Open [Internet]. 2024 Mar 1 [cited 2024 May 1];9. Available from: https://www.esmoopen.com/article/S2059-7029(24)00685-9/fulltext
2. Chemi F, Pearce SP, Clipson A, Hill SM, Conway AM, Richardson SA, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer [Internet]. 2022 Aug 8 [cited 2022 Aug 21]; Available from: https://www.nature.com/articles/s43018-022-00415-9
3. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary | Nature Communications [Internet]. [cited 2024 Aug 22]. Available from: https://www.nature.com/articles/s41467-024-47195-7
4. Avanzo M, Wei L, Stancanello J, Vallières M, Rao A, Morin O, et al. Machine and deep learning methods for radiomics. Medical Physics. 2020;47(5):e185–202.
5. Real-world outcomes in patients with unresected stage III non-small cell lung cancer - ProQuest [Internet]. [cited 2021 Dec 28]. Available from: https://www.proquest.com/docview/2174251496?accountid=12253&parentSessionId=m%2B6px1RoRy7vdQNTAQZzAuyQpwhaL2MoSIQPkUfR%2BPw%3D&pq-origsite=primo

Open Days


Register your interest for this project



Where will I study?

Faculty of Biology, Medicine and Health

Tackle real world challenges, make a difference, and elevate your career with postgraduate research in the Faculty of Biology, Medicine and Health at Manchester. From biochemistry to neuroscience, cancer sciences to medicine, audiology to mental health and everything in between, we offer a wide range of postgraduate research projects, programmes and funding which will allow you to immerse yourself in an area of research you’re passionate about.

Why study at Faculty of Biology, Medicine and Health?

Ranked the best place to live in the UK (The Economist Global Liveability Index, 2022), Manchester boasts world-class culture, iconic sports, a thriving music and food scene, and much more. It's not just a place to research, it's a place to call home.

Experience PhD life as part of a diverse postgraduate research community of more than 1,000 postgraduate researchers at the 29th most international university in the world (Times Higher Education, 2023).

With 93% of research activity at the University rated as 'world-leading' or 'internationally excellent' (Research Excellence Framework, 2021), you'll get the chance to have an impact on global health and science challenges.

1000+

postgraduate students

220

PhDs

6

ranked in UK - QS (2025)

Manchester  United Kingdom

main campus

Upcoming Open Days & Webinars


About Faculty of Biology, Medicine and Health

At Manchester, postgraduate researchers are at the heart of our mission to tackle pressing global challenges in biological, medical and healthcare sciences - and you could be too.

By choosing Manchester for your postgraduate research, you’ll be joining a university with an exceptional research reputation, where 93% of research is world-leading or internationally excellent (REF, 2021) and where your work will have real-world impact.

You’ll research in world-class facilities alongside leading experts at the forefront of innovation, collaborating across disciplines to pioneer new treatments, advance scientific knowledge, and improve healthcare globally.

Supported by our dedicated Doctoral Academy and strong industry links, you'll experience PhD life in a vibrant, welcoming and diverse postgraduate research community.

And you’ll leave with the specialist knowledge, research experience and transferable skills that will shape your future in academia, research or industry.





Main campus

The University of Manchester

Manchester

North West

United Kingdom

PhD saved sucessfully

(International Partnership Studentship) Using white matter network alterations relating to stroke risk to predict cognitive and health outcomes

The project aims to investigate how age-related changes in brain white matter impact upon cognitive and health outcomes. Using advanced software and MRI data from the UK Biobank, the researchers will create effective cross-sectional and longitudinal models of how white matter abnormalities predict cognitive function. Read more
More details

(MB-PhD) Gene regulatory networks driving metastatic progression in oesophageal adenocarcinoma

Oesophageal adenocarcinoma (OAC) incidence is increasing and yet survival rates remain very poor. There are limited treatment options, especially for metastatic disease, which is especially problematic as patients usually present with late stage disease. Read more
More details

(MB-PhD) MYST Histone Acetyltransferases as Therapeutic Targets in Acute Myeloid Leukaemia

Cytotoxic chemotherapy has been the standard of care for treatment of acute myeloid leukaemia (AML) for the last 50 years. Unfortunately, more often than not, it fails to cure patients, and the 5 years survival rate for all-comers with AML is only around 20%. Read more
More details

(MB-PhD)Immunomodulation in multiple myeloma

Multiple myeloma is a devastating B-cell malignancy for which there is no cure. The development of immunomodulatory drugs (IMiDs) has proved transformative to multiple myeloma care, however, their remain unanswered questions related to the mechanism of action of this important drug class. Read more
More details

(MRC DTP CASE) Developing a cortical organoid model of genetic autism to understand early brain development

Neurodevelopmental conditions including autism and ADHD affect 4-8% of the paediatric population. These conditions present in the preschool period, are highly heritable and can severely affect quality of life, academic and occupational functioning. Read more
More details

(MRC DTP CASE) Drug Binding on human G-Protein Coupled Receptors under Tension-Altered Biomechanics in Diseases

Integral membrane proteins (MPs) constitute a significant part of the genome and are targets of ~30% of therapeutics. However, structural and functional understanding of these proteins often lags behind that of their soluble counterparts. Read more
More details

(MRC DTP) Circadian mechanisms in psoriasis: translating genomic and computational analysis to clinical care.

Despite numerous lines of evidence supporting a role for the circadian clock regulating multiple immunological axes, the dominant cell type driving rhythmic disease expression in psoriasis remains undetermined and there has been no progress on time-of-day regulation of psoriasis. Read more
More details

(MRC DTP) Combinatorial targeting of multiple disease mechanisms in drug-resistant epilepsy using microRNA inhibitors

Epilepsy is one of the most common chronic neurological diseases, affecting ~70 million people worldwide. Epilepsy is characterised by susceptibility to spontaneous seizures, and can also include challenges with cognition, sleep and mental health. Read more
More details

(MRC DTP) Controlling G-protein coupled receptors to understand and treat obesity

The socioeconomic burden of obesity is ever increasing. Therefore, deciphering the neural substrates that control energy intake, expenditure and partitioning is an important step to developing novel treatments to reduce obesity rates. Read more
More details

(MRC DTP) Decoding the Brain-Immune Axis: Neuronal Circuitry and Metabolic Impact on Immune Responses

The immune system's response is intricately linked to nutritional status, with fasting and caloric restriction reducing inflammatory damage and extreme dietary perturbations increasing susceptibility to infection and inflammatory disorders. Read more
More details